Keryx Biopharmaceuticals

J.P. Morgan Reiterates Overweight on Keryx Biopharmaceuticals Following Investor Meetings with Management

In a research report issued Friday, J.P.

Analysts Weigh In on Two Biotech Stocks: Keryx Biopharmaceuticals (KERX), Conatus Pharmaceuticals Inc (CNAT)

Analysts are weighing in on two biotechnology companies Keryx Pharmaceutical (NASDAQ:KERX) and Conatus Pharmaceuticals Inc (NASDAQ:CNAT), with mixed ratings. Keryx Pharmaceutical BTIG analyst Hartaj Singh came out with a …

BTIG Remains Bearish on Keryx Biopharmaceuticals (KERX) Despite Fexeric EU Approval; Reduces Price Target

BTIG analyst Hartaj Singh weighed in today with a pessimistic view on Keryx Biopharmaceuticals (NASDAQ:KERX), after the company announced that its lead candidate Aurxyia (Fexeric in the …

Brean Capital Slashes Price Target for Keryx Biopharmaceuticals (KERX); Here’s Why

In a research report issued today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of Keryx Biopharmaceuticals (NASDAQ:KERX), while reducing the …

Thursday’s Market Insights: Keryx Biopharmaceuticals (KERX), Caterpillar Inc. (CAT), Arrowhead Research Corp (ARWR), Conatus Pharmaceuticals Inc (CNAT)

Keryx Biopharmaceuticals (NASDAQ:KERX) rose more than 12% in pre-market trading up to $4.40 after this morning’s announcement that the company received approval in Europe …

Company Update (NASDAQ:KERX): Keryx Biopharmaceuticals Receives European Approval for Fexeric(R) (ferric citrate coordination complex) for the Treatment of Hyperphosphatemia in Adults With Chronic Kidney Disease

Keryx Biopharmaceuticals (NASDAQ:KERX) announced that the European Commission has approved Fexeric® (ferric citrate coordination complex) for the control of elevated serum phosphorus levels, or …

Brean Capital Defends Keryx Biopharmaceuticals (KERX) Following Recent Selloff

In a research report published Friday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of Keryx Biopharmaceuticals (NASDAQ:KERX) with a $22 …

Insider Selling News: Keryx Biopharmaceuticals (KERX), Facebook Inc (FB), Celgene Corporation (CELG), Illumina, Inc. (ILMN)

Recently, various executives have taken part in insider selling activity for the stocks of Keryx Biopharmaceuticals (NASDAQ:KERX), Facebook Inc (NASDAQ:FB), Celgene Corporation (NASDAQ:CELG), and Illumina, Inc. (NASDAQ:ILMN).

Monday Morning Pre-Market Insights: MannKind Corporation (MNKD), Keryx Biopharmaceuticals (KERX), Transocean LTD (RIG), Inovio Pharmaceuticals Inc (INO)

MannKind Corporation (NASDAQ:MNKD) shares spiked 6.28% in pre-market trading to $4.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts